JOP20170147A1 - تركيبات خاصة بالعيون - Google Patents

تركيبات خاصة بالعيون

Info

Publication number
JOP20170147A1
JOP20170147A1 JOP/2017/0147A JOP20170147A JOP20170147A1 JO P20170147 A1 JOP20170147 A1 JO P20170147A1 JO P20170147 A JOP20170147 A JO P20170147A JO P20170147 A1 JOP20170147 A1 JO P20170147A1
Authority
JO
Jordan
Prior art keywords
epithelial
induced
damage induced
ocular
ophthalmic compositions
Prior art date
Application number
JOP/2017/0147A
Other languages
English (en)
Inventor
DELGADO GANAN Isabel
Marchan Sancho Sandra
Izquierdo Torres Francisca
Original Assignee
Salvat Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvat Lab Sa filed Critical Salvat Lab Sa
Publication of JOP20170147A1 publication Critical patent/JOP20170147A1/ar
Application granted granted Critical
Publication of JOP20170147B1 publication Critical patent/JOP20170147B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة خاصة بالعيون تشتمل على زيت خروع وثلاثي جليسريد ذو سلسلة متوسطة، وباستخدامها في الطب، تحديدا لعلاج و/أو الوقاية من مرض عيني منتقى من المجموعة التي تتكون من جفاف العين، التهاب الملتحمة، التهاب الأدمة، التهاب الجفن، الشتر الداخلي، متلازمة الجفن المترهل، اعتلال العين الدرقي المنشأ، الظفرة، التهاب الملتحمة اللارتخائي، التلف الظهاري المستحث بالمواد الحافظة، تلف الغرفة الظهاري أو السابق المستحث بجراحة العين، خلل الخلية الحوفي، تقرحات القرنية المستحثة بالعوامل الفيزيائية او الكيميائية، التهاب القرنية، التهاب ظاهر الصلبة والتهاب القزحية.
JOP/2017/0147A 2016-07-07 2016-07-07 تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة JOP20170147B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16382321.4A EP3266446B1 (en) 2016-07-07 2016-07-07 Ophthalmic composition comprising castor oil and medium chain triglyceride

Publications (2)

Publication Number Publication Date
JOP20170147A1 true JOP20170147A1 (ar) 2019-01-30
JOP20170147B1 JOP20170147B1 (ar) 2021-08-17

Family

ID=56404062

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0147A JOP20170147B1 (ar) 2016-07-07 2016-07-07 تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة

Country Status (14)

Country Link
US (1) US10660848B2 (ar)
EP (1) EP3266446B1 (ar)
JP (1) JP7224095B2 (ar)
CN (1) CN107582605A (ar)
DK (1) DK3266446T3 (ar)
ES (1) ES2706535T3 (ar)
HR (1) HRP20190036T1 (ar)
JO (1) JOP20170147B1 (ar)
LT (1) LT3266446T (ar)
PL (1) PL3266446T3 (ar)
PT (1) PT3266446T (ar)
RS (1) RS58292B1 (ar)
RU (1) RU2756758C2 (ar)
SI (1) SI3266446T1 (ar)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11903986B2 (en) 2016-08-19 2024-02-20 Akrivista Llc Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
KR101892865B1 (ko) * 2017-08-16 2018-08-28 계명대학교 산학협력단 마퀴베리를 유효성분으로 함유하는 아토피성 피부염 예방 또는 치료용 조성물
CN114376961A (zh) 2017-08-18 2022-04-22 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
WO2019138379A1 (en) 2018-01-12 2019-07-18 Metimedi Pharmaceuticals Co., Ltd. Methods of treating chronic inflammatory diseases
KR102556874B1 (ko) * 2018-02-14 2023-07-18 동국제약 주식회사 비스포스포네이트 및 콜레칼시페롤을 함유하는 경구용 에멀젼 조성물 및 그 제조방법
PH12020551313B1 (en) * 2018-02-28 2024-02-28 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
EP4349327A3 (en) * 2018-08-28 2024-07-24 Cloudbreak Therapeutics, LLC Emulsion formulations of multikinase inhibitors
JP2020075918A (ja) * 2018-11-02 2020-05-21 千寿製薬株式会社 角膜上皮創傷治癒促進用の眼科用組成物
CA3122359A1 (en) * 2018-12-06 2020-06-11 Lipicare Life Sciences Ltd. Vitamin d micro-emulsions and uses thereof
CA3120453A1 (en) * 2018-12-10 2020-06-18 EternaTear, Inc. Ophthalmic formulations providing durable ocular lubrication
CA3126333A1 (en) * 2019-01-09 2020-07-16 Ken-ichi YAMADA Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases
JP2022529823A (ja) * 2019-04-22 2022-06-24 アレグロ オフサルミックス エルエルシー ドライアイの治療に使用可能な組成物および方法
IT201900007202A1 (it) * 2019-05-24 2020-11-24 Pavia Farm S R L Composizione a base di vitamine liposolubili ad elevato assorbimento enterico
RU2706703C1 (ru) * 2019-08-19 2019-11-20 Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" Раствор увлажняющий офтальмологический
GB202010829D0 (en) * 2020-07-14 2020-08-26 Exonate Ltd Compounds for treatment of neovascular diseases
CN111973554A (zh) * 2020-09-03 2020-11-24 浙江目中明生物科技有限公司 一种护眼水
MX2023010788A (es) * 2021-03-16 2023-09-25 Unilever Ip Holdings B V Composicion cosmetica para el cuidado de la piel.
US11951123B2 (en) 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
US12397017B2 (en) 2022-01-12 2025-08-26 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
US11471475B1 (en) 2022-03-08 2022-10-18 Ralph P. Stone Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery
US11679078B1 (en) 2022-03-08 2023-06-20 EternaTear, Inc. Ophthalmic formulations and related methods
CN115887356B (zh) * 2022-11-21 2025-06-27 山东诺明康药物研究院有限公司 一种地夸磷索钠离子敏感型凝胶剂及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3102593A1 (de) * 1981-01-27 1982-09-02 Dr. Thilo & Co GmbH, 8021 Sauerlach Arzneimittelzubereitung zur anwendung am auge
JP3410364B2 (ja) * 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
EP0998925A4 (en) * 1997-05-26 2003-02-26 New Vision Co Ltd TOPICAL ADMINISTRATION COMPOSITIONS CONTAINING VITAMINS D AND VITAMINS K
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
WO2004098592A1 (ja) * 2003-05-06 2004-11-18 Senju Pharmaceutical Co. Ltd. オキサゾリジノン誘導体含有組成物
DE602004017477D1 (de) * 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
CN100478025C (zh) * 2005-03-25 2009-04-15 中国科学院上海药物研究所 一种环孢菌素a眼用微乳制剂及其制备方法
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101028240B (zh) 2007-03-29 2010-06-09 中国科学院上海药物研究所 眼用微乳/亚微乳原位凝胶制剂及其制备方法
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US20100286121A1 (en) * 2007-11-05 2010-11-11 Rohrs Brian R Water-Immiscible Materials as Vehicles for Drug Delivery
CN101385697B (zh) * 2008-10-30 2012-10-03 中国科学院上海药物研究所 氟比洛芬酯眼用纳米乳-原位凝胶制剂及其制备方法
US8496976B2 (en) * 2009-06-05 2013-07-30 Allergan, Inc. Artificial tears and therapeutic uses
IT1404931B1 (it) * 2010-06-11 2013-12-09 Medivis S R L Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
CN102370617B (zh) * 2010-08-13 2013-09-11 中国科学院上海药物研究所 石杉碱甲眼用微乳制剂及其制备方法
EP2659903B1 (en) * 2010-12-28 2016-09-14 Hanlim Pharmaceutical Co., Ltd. Nanoemulsion-type ophthalmic composition
US9610245B2 (en) * 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
JP2013018764A (ja) 2011-07-14 2013-01-31 Kao Corp 上皮型ナトリウムチャネル活性化剤
KR102107471B1 (ko) * 2011-11-24 2020-05-07 토요 슈가 리파이닝 컴퍼니 리미티드 각결막 보호제 또는 각결막 장해 억제제
CA2858574C (en) 2011-12-07 2017-05-30 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
MX2014013714A (es) * 2012-05-11 2015-08-10 Cipla Ltd Composicion farmaceutica.
JP5084967B1 (ja) * 2012-06-08 2012-11-28 ライオン株式会社 高吸着性ビタミンａ含有ナノエマルション粒子を含む眼科用組成物及びその製造方法
JP6265500B2 (ja) 2012-12-18 2018-01-24 オリザ油化株式会社 ドライアイ予防・治療剤
PT2968139T (pt) * 2013-03-14 2018-06-18 Eyecro Llc Plataforma de entrega tópica de microemulsão
EP2978409B1 (en) 2013-03-27 2018-01-10 Comprehensive Drug Enterprises Ltd Ophthalmic composition, method for preparing the same, and use of the same
KR101492447B1 (ko) * 2013-05-20 2015-02-23 주식회사태준제약 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법
SG11201608729RA (en) 2014-05-01 2016-11-29 Integral Biosystems Llc Membrane-adherent self-assembled systems for treatment of ocular disorders
CN105496955A (zh) * 2015-12-11 2016-04-20 北京蓝丹医药科技有限公司 一种二氟泼尼酯眼用乳剂及其制备方法
CN105663141B (zh) 2016-03-24 2018-06-15 北京茗泽中和药物研究有限公司 二氟泼尼酯眼用乳剂
CN105726479B (zh) * 2016-03-24 2018-06-22 北京茗泽中和药物研究有限公司 环孢素眼用乳剂

Also Published As

Publication number Publication date
JOP20170147B1 (ar) 2021-08-17
RU2756758C2 (ru) 2021-10-05
PL3266446T3 (pl) 2019-05-31
ES2706535T3 (es) 2019-03-29
LT3266446T (lt) 2019-01-25
CN107582605A (zh) 2018-01-16
RU2017123797A3 (ar) 2020-09-18
EP3266446A1 (en) 2018-01-10
JP2018039781A (ja) 2018-03-15
RS58292B1 (sr) 2019-03-29
RU2017123797A (ru) 2019-01-09
SI3266446T1 (sl) 2019-02-28
US20180008538A1 (en) 2018-01-11
EP3266446B1 (en) 2018-11-21
JP7224095B2 (ja) 2023-02-17
PT3266446T (pt) 2019-01-30
HRP20190036T1 (hr) 2019-02-22
DK3266446T3 (en) 2019-02-11
US10660848B2 (en) 2020-05-26

Similar Documents

Publication Publication Date Title
JOP20170147A1 (ar) تركيبات خاصة بالعيون
HK1258588A1 (zh) 用於治疗眼科疾病的化合物和制剂
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
BR112014008759A2 (pt) tratamento de doença ocular
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
MY171920A (en) Prevention and treatment of ocular conditions
EA201170551A1 (ru) Способы лечения заболеваний глаз
NZ705624A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
MX388641B (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MY187552A (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
NZ746468A (en) Methods of treating ocular conditions
WO2015059122A3 (en) Sirna and their use in methods and compositions for inhibiting the expression of the orai1 gene
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
EA201891730A1 (ru) Офтальмологическая композиция для применения при лечении офтальмологических расстройств, связанных с изменениями роговично-конъюнктивальной поверхности
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
HK1246206A1 (zh) 用於治疗青光眼的组合物和方法
CL2019002839A1 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.
RU2016136333A (ru) Фармакологическая офтальмологическая композиция, используемая в коррекции пресбиопии, и ее введение
WO2015059116A3 (en) Sirna and their use in methods and compositions for inhibiting the expression of the flap gene
DK1937281T3 (da) Modulering af TRPV-ekspressionsniveauer
CR20170346A (es) Composiciones para el tratamiento de infecciones producidas por el ácaro demodex spp
TW201613596A (en) Ophthalmic suspension preparation